secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001213900-26-023440
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology reports positive Phase 1 data for LYMPHIR prior to CAR-T in DLBCL
--------------------------------------------------------------------------------

- Overall response rate 86% (57% complete response, 29% partial response) at one month in 14 patients.
- One-year progression-free survival 77% (95% CI 43-92%); overall survival 84% (95% CI 49-96%).
- LYMPHIR well-tolerated with no dose-limiting toxicities; no Grade ≥3 LYMPHIR-related immune AEs.
- Single LYMPHIR dose depleted circulating Tregs (median reduction 24 Tregs/µL); supports larger trial.
- Study enrolled high-risk relapsed/refractory DLBCL patients; all proceeded to CAR-T infusion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/0001213900-26-023440-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea0277423-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-023440

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer